Cantor Fitzgerald analyst Pete Stavropoulos upgraded Alector to Overweight from Neutral. The Alector Brain Carrier platform positions Alector to become a major player in the neurodegenerative space for drugs that leverage blood-brain barrier-crossing technology to enhance delivery to the brain, the analyst tells investors in a research note. The ABC platform has significant potential value, which is underappreciated at current levels, the firm says.
